NCT06138353View on ClinicalTrials.gov

Shuxuening Injection for the Prevention of CVS in Patients With aSAH(SXN-CVS)

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

January 24, 2024

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2025

Conditions
Subarachnoid Hemorrhage, Aneurysmal
Interventions
DRUG

Shuxuening injection or placebo

Shuxuening injection treatment group : Shuxuening injection (specification: 10ml/branch, Lanzhi Group Wanrong Pharmaceutical Co., Ltd.), 20 ml (2 branches) + 5% dextrose injection 250 ml, intravenously, once a day, from the first day of postoperative, treatment for 1 course of treatment, a total of 10-14 days.

Trial Locations (1)

100070

RECRUITING

Beijing Tiantan Hospital, Beijing

All Listed Sponsors
lead

Xiaolin Chen, MD

OTHER